FDA approves AstraZeneca ’s faslodex for expanded use in breast cancer
AstraZeneca ’s faslodex (fulvestrant) at 500mg has received approval from the US Food and Drug Administration (FDA) as monotherapy for expanded use in women with advanced breast cancer.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Pharmaceuticals | Women